OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.299

Related search